132 related articles for article (PubMed ID: 32344563)
1. Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
Deodhar AA; Miceli-Richard C; Baraliakos X; Marzo-Ortega H; Gladman DD; Blanco R; Das Gupta A; Martin R; Safi J; Porter B; Shete A; Rosenbaum JT
ACR Open Rheumatol; 2020 May; 2(5):294-299. PubMed ID: 32352653
[TBL] [Abstract][Full Text] [Related]
2. Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib.
Perrone V; Losi S; Rogai V; Antonelli S; Fakhouri W; Giovannitti M; Giacomini E; Sangiorgi D; Degli Esposti L
Rheumatol Ther; 2020 Sep; 7(3):657-665. PubMed ID: 32683611
[TBL] [Abstract][Full Text] [Related]
3. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis.
Klint S; Feldwisch J; Gudmundsdotter L; Dillner Bergstedt K; Gunneriusson E; Höidén Guthenberg I; Wennborg A; Nyborg AC; Kamboj AP; Peloso PM; Bejker D; Frejd FY
MAbs; 2023; 15(1):2209920. PubMed ID: 37184136
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.
Galletti C; Barbieri MA; Ciodaro F; Freni F; Galletti F; Spina E; Galletti B
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111387
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project.
Barbieri MA; Viola A; Cicala G; Spina E; Fries W
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552036
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.
Eshwar V; Kamath A; Shastry R; Shenoy AK; Kamath P
Pharmaceuticals (Basel); 2022 Nov; 15(11):. PubMed ID: 36355537
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study.
Parisi S; Becciolini A; Ditto MC; Rozza D; Zanetti A; Laganà A; Peroni CL; Centanaro Di Vittorio C; Degiovanni R; Realmuto C; Scirè CA; Priora M; Di Donato E; Santilli D; Mozzani F; Lucchini G; Ariani A; Gardelli L; Girelli F; Arrigoni E; Platè I; Bravi E; Paroli M; Caccavale R; Salvarani C; Sandri G; Lumetti F; Volpe A; Marchetta A; Fusaro E
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160074
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions associated with the use of biological agents.
Machado-Alba JE; Jiménez-Morales AL; Moran-Yela YC; Parrado-Fajardo IY; Valladales-Restrepo LF
PLoS One; 2020; 15(12):e0240276. PubMed ID: 33338057
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
11. Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study.
Barbieri MA; Cicala G; Cutroneo PM; Gerratana E; Palleria C; De Sarro C; Vero A; Iannone L; Manti A; Russo E; De Sarro G; Atzeni F; Spina E
J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32344563
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.
Iannone LF; Bennardo L; Palleria C; Roberti R; De Sarro C; Naturale MD; Dastoli S; Donato L; Manti A; Valenti G; D'Amico D; D'Attola S; De Francesco AE; Bosco V; Donato Di Paola E; Nisticò SP; Citraro R; Russo E; De Sarro G
PLoS One; 2020; 15(11):e0241575. PubMed ID: 33141869
[TBL] [Abstract][Full Text] [Related]
13. Real-World Safety Profile of Biologics Used in Rheumatology: A Six-Year Observational Pharmacovigilance Study in the Calabria Region.
Gagliardi A; Iaquinta FS; Grembiale RD; De Sarro C; Fabiano A; Fraija D; Palleria C; Romeo R; De Francesco AE; Naturale MD; Citraro R; Gallelli L; Leo A; De Sarro G
Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365146
[No Abstract] [Full Text] [Related]
14. Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).
Palleria C; Iannone L; Leporini C; Citraro R; Manti A; Caminiti M; Gigliotti P; Grembiale RD; L'Andolina M; Muccari G; Naturale MD; Olivo D; Pagano Mariano G; Pellegrini R; Varcasia G; Abdalla K; Russo E; Ursini F; De Sarro G
PLoS One; 2018; 13(10):e0205134. PubMed ID: 30356301
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
